• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A process for preparing pliable soft tissue specimen which are resistant to cracking and devoid of viable cells includes the steps of treating native soft tissue obtained from a donor by a gradually increasing gradient of aliphatic alcohol or other suitable water miscible polar organic solvent until the last alcohol (or other solvent) solution has at least 25% by volume of the organic liquid. Thereafter, the tissue specimen is treated with a solution containing glycerol or low molecular weight (<1000D) polyethylene glycol, and polyethylene glycol of a molecular weight between approximately 6,000 to 15,000 D and heparin. Thereafter, the tissue specimen is briefly immersed in aqueous heparin solution, frozen and lyophilized. The tissue specimen is suitable for implantation as a homograft or xenograft, with or without rehydration.
    公开号:US20010004715A1
    申请号:US09/103,874
    申请日:1998-06-24
    公开日:2001-06-21
    发明作者:Carlos M. G. Duran；David T. Cheung；David C. Pang
    申请人:INTERNATIONAL HEART INSTITUTE OF MONTANA；
    IPC主号:A61L27-3691
    专利说明:
    [0001] 1. Field of the Invention [0001]
    [0002] The present invention is in the field of implant materials. More particularly, the present invention is directed to compliant dehydrated implant materials which have no viable cells, and can be stored and transported without being immersed in liquid. The present invention is also directed to the process of producing said implant materials. [0002]
    [0003] 2. Brief Description of the Prior Art [0003]
    [0004] The use of autografts, homografts and xenografts for augmenting or replacing defective tissues in humans and animals has been known for a long time. From the standpoint of providing suitable materials for implantation, augmenting or replacing hard tissues, such as bone, presents a different type of problem than augmenting or replacing soft tissues. In the selection of substitute materials for hard tissue graft, the strength and hardness of the graft are important whereas compliance and flexibility are, generally speaking, less crucial. [0004]
    [0005] On the other hand, in the selection of soft tissue materials for implantation, compliance and flexibility of the graft material are usually of utmost importance because the soft tissue replacement material usually must closely match the healthy functional tissue that will be replaced. In this regard it must be remembered that natural soft tissue containing collagen is strong and able to withstand repeated three-dimensional stress as well as bending and deformation. Often natural soft tissue acts as a physical barrier that must maintain its structural integrity. Ideally, replacement or augmentation soft tissue that is utilized in implantation should have the same characteristics as the natural soft tissue that it replaces, and should be easy to obtain, store and transport. These, however are difficult goals that the prior art has been striving to attain, and up to the present invention only with moderate success. [0005]
    [0006] More particularly, in accordance with one major approach in the prior art to preserve soft tissue for eventual implantation, tissues of human or animal origins have been treated with chemical modifiers/preservatives, such as glutaraldehyde, which cross-links collagen and other proteins. The glutaraldehyde treated tissues have been shown to be adequately resistant to mechanical fatigue as well as biodegradation when implanted in human patients. However, the glutaraldehyde cross-linking alters the viscoelastic properties of tissues, and therefore, as a result of host response undesirable calcification and build-up of peripheral granulation tissues usually occur in the implants with time. Glutaraldehyde is an effective biocidal (sterilyzing) agent, but when exposed to air it slowly loses its biocidal effectiveness. Therefore, the tissue intended for implantation (bioprosthesis) must be kept in glutaraldehyde solution during storage and transportation and the package including the glutaraldehyde soaked bioprosthesis must be kept tightly sealed. Moreover, it must not be exposed to significantly elevated temperature. Because of these requirements the costs of utilizing glutaraldehyde-treated soft tissue bioprostheses are high. Glutaraldehyde is toxic, and therefore it must be carefully removed from the bioprosthesis by rinsing before implantation. This represents still another disadvantage of glutaraldehyde-treated bioprostheses. [0006]
    [0007] Another major approach for providing soft tissue bioprosthesis in the prior art utilizes liquid sterilants other than glutaraldehyde. Some of these alternative approaches also avoid the calcification problems associated with glutaraldehyde treated implants. However, in accordance with these processes also, to avoid brittleness and to more-or-less maintain the physical integrity of the bioprostheses the tissues have to be maintained, stored and transported in liquid media up to the time immediately preceding implantation. [0007]
    [0008] Still another alternative method for providing soft tissue bioprostheses is the use of cryo-preserved fresh tissues of homograft (tissue from the same species). Because of recent advances in cryo-preservation, the cryo-preserved fresh tissues have recently made homograft implants relatively more successful and more accepted as an alternative to glutaraldehyde-preserved xenograft. A serious disadvantage of cryo-preserved bioprostheses is the difficulty to assure that they are free of infectious disease agents. The costs of preparing and handling of cryo-preserved bioprosthesis tissues is also very high because of the need for keeping the tissues at all times below the usual or normal freezer temperatures. [0008]
    [0009] From among the numerous patent disclosures in the prior art directed to preparing and/or preserving biological tissue for implantation or other use as replacement tissue, U.S. Pat. Nos. 5,116,552 (Morita et al.) and 5,336,616 (Livesey et al.) are mentioned as of interest to the present invention. U.S. Pat. No. 5,116,552 (Morita et al.) describes a process for preparing lyophilized collagen sponge for medical applications, such as artificial skin. The process of this reference comprises the steps of impregnating cross-linked collagen sponge with an aqueous solution of a hydrophilic organic solvent, freezing the sponge and thereafter vacuum drying (lyophilizing) it. However, the resulting freeze-dried product is not pliable and is not protected from cracking because the water and the hydrophilic solvent or solvents have been removed in the lyophilization step. U.S. Pat. No. 5,336,616 (Livesey et al.) describes treatment of soft tissue obtained from a source, such as a cadaver, with solutions containing antioxidants, protease inhibitors and antibiotics (stabilizing solution), with enzymes and detergents to remove viable antigenic cells (processing solution), and after decellularization with a cryopreservative solution that prevents destructive ice crystal formation while the tissue is frozen. The cryo-preserving solution may include a combination of organic solvent and water. After lyophilization the product is stored and transported in a sealed container in an inert gas atmosphere, thus protected from atmospheric moisture. Prior to implantation the tissue is rehydrated and must be restored with immunotolerable viable cells to produce a permanently acceptable graft for implantation. [0009]
    [0010] Still other disclosures pertaining to the preparation and/or preservation of biological tissue for implantation, or related subjects, can be found in U.S. Pat. Nos. 2,106,261; 2,610,625; 2,645,618; 3,939,260; 4,277,238; 4,280,954; 4,300,243; 4,383,832; 4,578,067; 4,703,108; 4,704,131; 4,760,131; 4,801,299; 4,911,915; 5,028,597; 5,131,850; 5,674,290 and U.K. Patent Specification 716,161. [0010] SUMMARY OF THE INVENTION
    [0011] It is an object of the present invention to provide a soft tissue graft suitable for implantation in humans or other mammals which graft after rehydration has substantially the same mechanical properties as the natural soft tissue from which the graft was obtained. [0011]
    [0012] It is another object of the present invention to provide a soft tissue graft that satisfies the foregoing objective, that is also devoid of viable cells and does not require inoculation with viable cells prior to implantation. [0012]
    [0013] It is still another object of the present invention to provide a soft tissue graft that satisfies the foregoing objectives, that can be stored and transported in a dehydrated form. [0013]
    [0014] The foregoing and other objects and advantages are attained by a soft tissue preparation that in its dehydrated state is compliant, resists cracking, is devoid of viable cells and which is obtained by successively treating natural soft tissue: [0014]
    [0015] with liquid compositions of gradually increasing concentrations of a C[0015] 1-C3 alcohol, or other polar water miscible organic solvent in water, until the last of said liquid compositions contains at least approximately 25% by volume alcohol, or the other organic solvent, or mixtures thereof, the balance being water;
    [0016] thereafter with a second liquid composition of aqueous glycerol or of low molecular weight (<1000 D) polyethylene glycol, containing the glycerol or the low molecular weight polyethylene glycol, or mixtures thereof, in a concentration range of approximately 10 to 50% by volume, said second liquid composition also containing approximately 3-20% weight by volume polyethylene glycol of a molecular weight in the range of 6,000 D to 15,000 D and approximately 2 to 75 unit per milliliter heparin of a molecular weight greater than approximately 3 KD; [0016]
    [0017] thereafter draining excess liquid from the soft tissue so treated; [0017]
    [0018] thereafter immersing the soft tissue in an aqueous heparin solution of approximately 20 to 500 unit per milliliter concentration, and [0018]
    [0019] thereafter freezing the tissue and lyophilizing the tissue to dryness. [0019]
    [0020] The features of the present invention can be best understood together with further objects and advantages by reference to the following detailed description of specific examples and embodiments. [0020] DESCRIPTION OF THE PREFERRED EMBODIMENTS
    [0021] The following specification sets forth the preferred embodiments of the present invention. The embodiments of the invention disclosed herein are the best modes contemplated by the inventors for carrying out their invention, although it should be understood that various modifications can be accomplished within the parameters of the present invention. [0021]
    [0022] In accordance with the present invention soft tissue intended for graft in mammals, including humans, is first obtained from a source, such as cadavers. Bovine, ovine, porcine tissue and soft tissue obtained from other animals, such as sheep, serve as examples. Human soft tissue may also be used. Homografts, that is tissues implanted in the same species as the donor, as well as xenografts, that is tissues implanted in species different from the donor, can be prepared in accordance with the present invention. The types of tissues used in accordance with the present invention are generally the same which are normally used in state-of-the-art surgical procedures involving implantations of soft tissues, primarily in humans. Examples of tissues frequently utilized in these procedures are pericardium, aortic and pulmonary roots, tendons, ligaments, skin, peritonium, pleura, mitral and tricuspid valves. [0022]
    [0023] The soft tissue excised from the donor is usually trimmed to remove loose excess or unneeded tissue and fat. Usually the tissue is then kept in saline solution. Thereafter, and in accordance with the present invention, the tissue is treated in a first aqueous solution containing a C[0023] 1-C3 alcohol in relatively low concentration (approximately 15-35), and thereafter in a second aqueous solution of greater alcohol concentration, in the range of approximately 25 to 75% volume by volume. (All concentrations described in this application are volume by volume, unless specifically stated otherwise.) The purpose of the treatment of the tissue specimen with the first and second solutions is to gradually replace the water content of the specimen with alcohol. Methyl, ethyl and iso-propyl alcohols can be used for this purpose with ethyl alcohol being preferred. Other, non-toxic polar and water miscible organic solvents e.g. acetonitrile, acetone or methyl-ethyl ketone can also be used instead of the above-listed alcohols, and mixtures of alcohols and organic solvents are also suitable for use in the invention. Preferably, the first solution contains approximately 25% ethyl alcohol, the balance being water, and the second solution contains approximately 50% ethyl alcohol, the balance being water.
    [0024] Those skilled in the art will readily recognize that the foregoing manipulations represent treatment of the tissue specimen with a stepwise increasing gradient of alcohol (or other suitable non-toxic water miscible organic solvent) concentration, until a concentration of at least approximately 25%, preferably approximately 50%, and at most approximately 75% alcohol (or other suitable solvent) concentration is reached. Instead of treating the tissue specimen with the aforesaid concentration gradient in two steps, the specimen could also be treated with the gradient in three or more steps, or even with a continuously increasing gradient until the upper limit of the alcohol (or other suitable solvent) concentration is reached. The treatment with the increasing gradient of alcohol (or other suitable solvent) concentration is conducted at ambient temperature and is best performed by immersing the tissue specimen in the solutions. The timing of the exposure of the tissue specimen to these solutions is not critical and is somewhat dependent on the thickness of the specimen. However sufficient time must be given for the solution to penetrate the specimen. Typically, 30 minutes are sufficient and in the preferred embodiments of the process of the invention the tissue specimen are kept for approximately 30 minutes in each of the first and second alcohol solutions. [0024]
    [0025] After immersion (treatment) in the above-described alcohol solutions, the tissue specimen is immersed (treated) in a third solution that contains approximately 10 to 50% glycerol, approximately 3 to 20% weight by volume polyethylene glycol of a molecular weight in the range of 6,000 D to 15,000 D and approximately 2 to 75 unit per milliliter heparin of a molecular weight greater than approximately 3 KD. Preferably, the third solution contains approximately 20% glycerol, approximately 5% (weight by volume) polyethylene glycol that has a molecular weight of approximately 8,000 D and approximately 50 unit per milliliter heparin. Instead of glycerol, a low molecular weight (<1000 D) polyethylene glycol can be included in the third solution. The duration of immersion in the third solution is also not critical, approximately 30 minutes are sufficient for very thin tissues such as ovine, porcine, bovine or human pericardium, but for thicker tissues longer times of exposure, such as 6 hours, or preferably 12 hours are convenient and preferred. [0025]
    [0026] After treatment with the third solution, the tissue specimen is removed therefrom and excess liquid is allowed to drain from the specimen. The specimen is then briefly (for seconds as in a quick dip) immersed in, or is otherwise treated with aqueous heparin solution of approximately 20 to 500 unit/ml concentration, and preferably of approximately 250 ml/unit concentration, then the heparin solution is allowed to drain off. Thereafter, the specimen is frozen in a manner usual in the art for freezing specimens prior to lyophilization. Those skilled in the art understand that freezing is usually conducted in a freezer of ultra-low temperature, that is between approximately −60° C.-−80°C. After freezing, the tissue specimen is lyophilized (dried in vacuo) in a manner known in the art. [0026]
    [0027] Tissue samples processed in accordance with the invention tend to be translucent and have a slight yellowish tint in color. Unlike tissues lyophilized from 100% water or physiological saline solution, the tissues of the invention are pliable, compliant and do not crack or break as a result of physical manipulations. [0027]
    [0028] For use in surgical procedures as an implant, and for most tests conducted in accordance with the present invention to compare the treated tissues with fresh tissues, the lyophilized tissues are first rehydrated in physiological buffered saline. This is done by treating, preferably by immersing, the lyophilized tissue of the invention in physiological buffered saline solution for approximately 5 minutes to one hour. The rehydrated tissues of the invention have an appearance that is practically indistinguishable from the appearance of the fresh tissue. Rehydration is typically conducted at ambient temperature. It can be done, other than in saline, in the patient's own blood, in tissue culture medium, and in low percentage (<10%) ethyl alcohol solution. A preferred method of rehydrating tissue specimen in accordance with the present invention is in buffered saline of pH 7.4. [0028]
    [0029] As noted above, except for testing the tissue specimen of the present invention, rehydration is performed only prior to use of the tissue specimen for implantation. Otherwise the specimen are stored and transported at ambient temperature in a sealed container protected from atmospheric moisture. The lyophilized tissues can be readily sterilized by gas phase sterilization methods, and can also be implanted without first being rehydrated. [0029]
    [0030] The tissue specimen of the invention do not contain viable cells, but tests described below demonstrated that after rehydration the tissue specimen are not cytotoxic and are compatible for host endothelial cells to attach and proliferate on them. This attachment and proliferation of host cells and lack of cytotoxicity are important for long term survival of most implants. The tissues of the invention are hemocompatible and resistant to platelet aggregation and thrombus formation. Tests, described below, also demonstrated that the collagen fibers of the native tissue have remained substantially intact during the steps of the process of the invention, and are substantially intact in the rehydrated tissue. [0030] SPECIFIC EXAMPLES AND DESCRIPTION OF TESTS
    [0031] (a) preparation of lyophilized bovine or ovine pericardium [0031]
    [0032] Fresh bovine and ovine pericardium was cut into strips and squares were dissected to remove loose tissues and fat. The tissues were immediately placed in aqueous 25% ethyl alcohol solution for 30 minutes. The aqueous 25% ethyl alcohol solution was replaced by aqueous 50% ethyl alcohol solution for another 30 minutes. The second (50% ethyl alcohol) solution was then replaced for approximately 16 hours by a third solution containing 20% glycerol, 5% weight by volume polyethylene glycol (MW 8,000) and 50 unit/ml heparin (molecular weight >3 KD). The tissues were carefully removed from the third solution, excess liquid was allowed to drain from the tissues and the tissues were dipped in a heparin solution of 250 unit/ml for a few seconds, prior to freezing the tissues at −70°C. The completely frozen tissues were lyophilized to dryness. [0032]
    [0033] The lyophilized bovine or ovine pericardium tissues obtained above had a translucent appearance and a slight yellowish tint. They were pliable and did not crack or break by physical manipulations. They could be rehydrated by immersion in physiological buffered saline for approximately 5 minutes at ambient temperature. After rehydration, the tissues were indistinguishable in appearance from the native fresh tissues. [0033]
    [0034] Human fibroblasts and umbilical cord vein endothelial cells were cultured on the rehydrated pericardium tissues to study their biocompatibility. Round discs of the tissues were cut to fit the bottom of the wells of a 24 well culture plate. Plastic rings were placed on top of the tissues to hold the tissues down and to ensure a good seal at the edge of the tissues. Cells were seeded on the tissues in normal culture media for one week. At the end of the incubation period, tissues were recovered and cut into different portions for histology studies. Histological examination of the cross-section of the tissues showed a thin layer of endothelial cells adhering to the surface of the tissues. Cells on the tissues were also released by trypsin and counted. These results showed that the rehydrated tissues are not cytotoxic and are biocompatible for host cells to attach and proliferate. As is known, attachment and proliferation of endothelial cells and other connective tissue cells on cardiac implants is essential for the long term survival of the implant. [0034]
    [0035] The integrity of the collagen fibers in the treated tissues was examined by melting temperature measurements. For these, tissues were heated in phosphate buffered saline from 37°C. until they shrunk. The shrinkage temperature of the fresh native tissues and of the lyophilized and rehydrated tissues in accordance with the present invention was approximately the same, at approximately 63+1°C., indicating that the collagen fibers remained intact throughout the lyophilization and rehydration process. [0035]
    [0036] (b) preparation of lyophilized sheep aortic and pulmonary roots [0036]
    [0037] Aortic and pulmonary roots of donor sheep were also treated with the aqueous 25% ethyl alcohol, aqueous 50% ethyl alcohol, aqueous 20% glycerol 5% polyethylene glycol, and subsequent heparin solution and lyophilized, as described above for the bovine and ovine pericardium. [0037]
    [0038] The treated roots were rehydrated and implanted as homografts in the descending aorta of host sheep. Our results show that after 100 days of implantation, the valves were competent and the roots do not appear different from the un-implanted native tissues. The hundred-day explant was free of fibrin deposition and free of host tissue reaction. The leaflets of the valve appeared intact and indistinguishable from the unimplanted valve by both gross observation and histological examination. [0038]
    权利要求:
    Claims (32)
    [1" id="US-20010004715-A1-CLM-00001] 1. A process for preparing a pliable soft tissue specimen, comprising the steps of:
    (1) treating natural soft tissue obtained from a donor with:
    (a) liquid compositions of gradually increasing concentrations of a polar organic solvent or solvents, until the last of said liquid compositions contains at least approximately 25% by volume of said solvent, or mixture of solvents, the balance being water, the solvent being selected from a group consisting of aliphatic alcohols having 1 to 3 carbons and other water miscible polar organic solvents;
    (b) thereafter with a second liquid composition of aqueous glycerol or of low molecular weight polyethylene glycol having a molecular weight less than approximately 1000 D, the glycerol or the low molecular weight polyethylene glycol, or mixtures thereof being in a concentration range of approximately 10 to 50% by volume, said second liquid composition also containing approximately 3-20% weight by volume of polyethylene glycol of a molecular weight in the range of 6,000 D to 15,000 D and approximately 2 to 75 unit per milliliter heparin of a molecular weight greater than approximately 3 KD;
    (2) thereafter briefly immersing the soft tissue in an aqueous heparin solution, and
    (3) thereafter freezing the tissue and lyophilizing the tissue to dryness.
    [2" id="US-20010004715-A1-CLM-00002] 2. The process in accordance with
    claim 1 wherein the polar organic solvents are selected from the group consisting of methyl alcohol, ethyl alcohol, iso-propyl alcohol, acetonitrile, acetone and methyl ethyl ketone.
    [3" id="US-20010004715-A1-CLM-00003] 3. The process in accordance with
    claim 2 wherein the polar organic solvent is ethyl alcohol.
    [4" id="US-20010004715-A1-CLM-00004] 4. The process in accordance with
    claim 1 wherein the natural soft tissue obtained from the donor is treated with liquid compositions of gradually increasing concentrations of a polar organic solvent or solvents, until the last of said liquid compositions contains at least approximately 50% by volume of said solvent, or mixture of solvents.
    [5" id="US-20010004715-A1-CLM-00005] 5. The process in accordance with
    claim 4 where the polar organic solvent is ethyl alcohol.
    [6" id="US-20010004715-A1-CLM-00006] 6. The process in accordance with
    claim 1 wherein the second liquid composition contains approximately 20% by volume of glycerol.
    [7" id="US-20010004715-A1-CLM-00007] 7. The process in accordance with
    claim 1 wherein the natural soft tissue is treated in succession with two liquid compositions of a polar organic solvent or solvents, the first of said compositions containing approximately 15 to 35% by volume of the solvent or solvents, the second of said composition containing approximately 25 to 75% by volume of the solvent or solvents.
    [8" id="US-20010004715-A1-CLM-00008] 8. The process in accordance with
    claim 7 wherein the polar organic solvent is ethyl alcohol.
    [9" id="US-20010004715-A1-CLM-00009] 9. The process in accordance with
    claim 1 further comprising the step of rehydrating the lyophilized tissue specimen.
    [10" id="US-20010004715-A1-CLM-00010] 10. A process for preparing a pliable soft mammalian tissue specimen, for eventual implantation in a mammal to replace or augment native tissue, the process comprising the steps of:
    (1) treating natural soft mammalian tissue obtained from a donor with:
    (a) liquid compositions of gradually increasing concentrations of an aliphatic alcohol or mixture of aliphatic alcohols having 1 to 3 carbon atoms, until the last of said liquid compositions contains at least approximately 25% by volume of said alcohol or mixture of alcohols, the balance being water;
    (b) thereafter with a second liquid composition of aqueous glycerol containing the glycerol in a concentration range of approximately 10 to 50% by volume, said second liquid composition also containing approximately 3-20% weight by volume polyethylene glycol of a molecular weight in the range of 6,000 D to 15,000 D and approximately 2 to 75 unit per milliliter heparin of a molecular weight greater than approximately 3 KD;
    (2) thereafter briefly immersing the soft tissue in an aqueous heparin solution of approximately 20 to 500 unit per milliliter concentration, and
    (3) thereafter freezing the tissue and lyophilizing the tissue to dryness.
    [11" id="US-20010004715-A1-CLM-00011] 11. The process in accordance with
    claim 10 wherein the aliphatic alcohol is ethyl alcohol.
    [12" id="US-20010004715-A1-CLM-00012] 12. The process in accordance with
    claim 11 wherein the natural soft tissue is treated with said compositions containing ethyl alcohol, until the last of said compositions contains at least approximately 50% by volume ethyl alcohol.
    [13" id="US-20010004715-A1-CLM-00013] 13. The process in accordance with
    claim 12 wherein the concentration of glycerol in the second liquid composition is approximately 20% by volume.
    [14" id="US-20010004715-A1-CLM-00014] 14. The process in accordance with
    claim 13 wherein the concentration of polyethylene glycol in the second liquid composition is approximately 5% weight by volume and the molecular weight of said polyethylene glycol is approximately 8,000 D.
    [15" id="US-20010004715-A1-CLM-00015] 15. The process in accordance with
    claim 14 wherein the natural soft tissue is treated in succession with two liquid compositions of ethyl alcohol, the first of said compositions containing approximately 15 to 35% by volume of ethyl alcohol, the second of said composition containing approximately 25 to 75% by volume of ethyl alcohol.
    [16" id="US-20010004715-A1-CLM-00016] 16. The process in accordance with
    claim 16 further comprising the step of rehydrating the lyophilized tissue specimen.
    [17" id="US-20010004715-A1-CLM-00017] 17. The process in accordance with
    claim 10 wherein the natural soft mammalian tissue is from pericardium, pleura, peritonium from aortic, pulmonary mitral or triscuspid valves, or from tendon or skin.
    [18" id="US-20010004715-A1-CLM-00018] 18. A pliable soft tissue specimen which has been prepared in a process comprising the steps of:
    (1) treating natural soft tissue obtained from a donor with:
    (a) liquid compositions of gradually increasing concentrations of a polar organic solvent or solvents, until the last of said liquid compositions contains at least approximately 25% by volume of said solvent, or mixture of solvents, the balance being water, the solvent being selected from a group consisting of aliphatic alcohols having 1 to 3 carbons and other water miscible polar organic solvents;
    (b) thereafter with a second liquid composition of aqueous glycerol or of low molecular weight polyethylene glycol having a molecular weight less than approximately 1000 D, containing the glycerol or the low molecular weight polyethylene glycol, or mixtures thereof being in a concentration range of approximately 10 to 50% by volume, said second liquid composition also containing approximately 3-20% weight by volume polyethylene glycol of a molecular weight in the range of 6,000 D to 15,000 D and approximately 2 to 75 unit per milliliter heparin of a molecular weight greater than approximately 3 KD;
    (2) thereafter briefly immersing the soft tissue in an aqueous heparin solution, and
    (3) thereafter freezing the tissue and lyophilizing the tissue to dryness.
    [19" id="US-20010004715-A1-CLM-00019] 19. The pliable soft tissue specimen in accordance with
    claim 18 wherein in the process of preparing the specimen the polar organic solvents are selected from the group consisting of methyl alcohol, ethyl alcohol, iso-propyl alcohol, acetonitrile, acetone and methyl ethyl ketone.
    [20" id="US-20010004715-A1-CLM-00020] 20. The pliable soft tissue specimen in accordance with
    claim 18 wherein in the process of preparing the specimen the natural soft tissue obtained from the donor is treated with liquid compositions of gradually increasing concentrations of a polar organic solvent or solvents, until the last of said liquid compositions contains at least approximately 50% by volume of said solvent, or mixture of solvents.
    [21" id="US-20010004715-A1-CLM-00021] 21. The pliable soft tissue specimen in accordance with
    claim 20 wherein in the process of preparing the specimen the polar organic solvent is ethyl alcohol.
    [22" id="US-20010004715-A1-CLM-00022] 22. The pliable soft tissue specimen in accordance with
    claim 18 wherein in the process of preparing the specimen the second liquid composition contains approximately 18% by volume of glycerol.
    [23" id="US-20010004715-A1-CLM-00023] 23. The pliable soft tissue specimen in accordance with
    claim 18 wherein in the process of preparing the specimen the natural soft tissue is treated in succession with two liquid compositions of a polar organic solvent or solvents, the first of said compositions containing approximately 15 to 35% by volume of the solvent or solvents, the second of said composition containing approximately 25 to 75% by volume of the solvent or solvents.
    [24" id="US-20010004715-A1-CLM-00024] 24. The pliable soft tissue specimen in accordance with
    claim 18 wherein the process of preparing the specimen further comprises the step of rehydrating the lyophilized tissue specimen.
    [25" id="US-20010004715-A1-CLM-00025] 25. A pliable soft tissue specimen, for eventual implantation in a mammal to replace or augment native tissue, which has been prepared in a process comprising the steps of:
    (1) treating natural soft mammalian tissue obtained from a donor with:
    (a) liquid compositions of gradually increasing concentrations of an aliphatic alcohol or mixture of aliphatic alcohols having 1 to 3 carbon atoms, until the last of said liquid compositions contains at least approximately 25% by volume of said alcohol or mixture of alcohols, the balance being water;
    (b) thereafter with a second liquid composition of aqueous glycerol containing the glycerol in a concentration range of approximately 10 to 50% by volume, said second liquid composition also containing approximately 3-20% weight by volume polyethylene glycol of a molecular weight in the range of 6,000 D to 15,000 D and approximately 2 to 75 unit per milliliter heparin of a molecular weight greater than approximately 3 KD;
    (2) thereafter briefly immersing the soft tissue in an aqueous heparin solution of approximately 20 to 500 unit per milliliter concentration, and
    (3) thereafter freezing the tissue and lyophilizing the tissue to dryness.
    [26" id="US-20010004715-A1-CLM-00026] 26. The soft tissue specimen in accordance with
    claim 25 wherein in the process of preparing the specimen the aliphatic alcohol is ethyl alcohol.
    [27" id="US-20010004715-A1-CLM-00027] 27. The soft tissue specimen in accordance with
    claim 26 wherein in the process of preparing the specimen the natural soft tissue is treated with said compositions containing ethyl alcohol, until the last of said compositions contains at least approximately 50% by volume ethyl alcohol.
    [28" id="US-20010004715-A1-CLM-00028] 28. The soft tissue specimen in accordance with
    claim 27 wherein in the process of preparing the specimen the concentration of glycerol in the second liquid composition is approximately 20% by volume.
    [29" id="US-20010004715-A1-CLM-00029] 29. The soft tissue specimen in accordance with
    claim 28 wherein in the process of preparing the specimen the concentration of polyethylene glycol in the second liquid composition is approximately 5 % weight by volume and the molecular weight of said polyethylene glycol is approximately 8,000 D.
    [30" id="US-20010004715-A1-CLM-00030] 30. The soft tissue specimen in accordance with
    claim 29 wherein in the process of preparing the specimen the natural soft tissue is treated in succession with two liquid compositions of ethyl alcohol, the first of said compositions containing approximately 15 to 35% by volume of ethyl alcohol, the second of said composition containing approximately 25 to 75% by volume of ethyl alcohol.
    [31" id="US-20010004715-A1-CLM-00031] 31. The soft tissue specimen in accordance with
    claim 25 wherein the process of preparing the specimen further comprises the step of rehydrating the lyophilized tissue specimen.
    [32" id="US-20010004715-A1-CLM-00032] 32. The soft tissue specimen in accordance with
    claim 25 wherein the natural soft mammalian tissue is from pericardium, pleura, peritonium, from aortic, pulmonary, mitral or tricuspid valves or from tendon and skin.
    类似技术:
    公开号 | 公开日 | 专利标题
    US6630001B2|2003-10-07|Compliant dehyrated tissue for implantation and process of making the same
    US6561970B1|2003-05-13|Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods
    US5855620A|1999-01-05|Matrix substrate for a viable body tissue-derived prosthesis and method for making the same
    US20200261222A1|2020-08-20|Biological tissue for surgical implantation
    US5192312A|1993-03-09|Treated tissue for implantation and methods of treatment and use
    US5922027A|1999-07-13|Articular cartilage heterografts
    US6352708B1|2002-03-05|Solution and method for treating autologous tissue for implant operation
    US20030228692A1|2003-12-11|Tissue decellularization
    WO1995028183A1|1995-10-26|Biological material pre-fixation treatment
    AU692330B2|1998-06-04|Method for reducing calcification of biological tissue used in implantable bioprostheses
    Van den Heever2020|Processed pulmonary homografts in the right ventricle outflow tract: an experimental study in the juvenile ovine model
    CA2188135C|2007-06-26|Biological material pre-fixation treatment
    McNally1989|Cryopreserved bioprostheses
    同族专利:
    公开号 | 公开日
    AU4829899A|2000-01-10|
    BR9912180A|2001-04-10|
    BR9912180B1|2011-05-31|
    AU751506B2|2002-08-15|
    WO1999066967A1|1999-12-29|
    CA2335604C|2008-09-23|
    HK1039284A1|2002-04-19|
    CA2335604A1|1999-12-29|
    EP1089776B1|2002-05-29|
    EP1089776A1|2001-04-11|
    US6277555B1|2001-08-21|
    HK1039284B|2006-06-30|
    DK1089776T3|2002-09-23|
    CN1245222C|2006-03-15|
    CN1306445A|2001-08-01|
    DE69901612T2|2003-02-13|
    AT218067T|2002-06-15|
    ES2178449T3|2002-12-16|
    US6630001B2|2003-10-07|
    DE69901612D1|2002-07-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20020120345A1|1998-06-30|2002-08-29|Lloyd Wolfinbarger|Plasticized soft tissue grafts, and methods of making and using same|
    WO2003047417A2|2001-12-03|2003-06-12|Merck & Co., Inc.|Ep4 receptor agonist, compositions and methods thereof|
    US20030135284A1|1998-06-30|2003-07-17|Katrina Crouch|Plasticized bone grafts and methods of making and using same|
    US20030217415A1|1998-06-30|2003-11-27|Katrina Crouch|Plasticized bone grafts and methods of making and using same|
    US20060039897A1|2002-03-26|2006-02-23|Tamar Lotan|Stinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue|
    US20060099272A1|2004-11-05|2006-05-11|Nanocyte Inc.|Compositions and kits including dehydrated stinging capsules and methods of producing and using same|
    US20060159769A1|2000-09-28|2006-07-20|Nanocyte Inc.|Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue|
    US20060234203A1|2005-04-19|2006-10-19|Nanocyte Inc.|Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent|
    US7632522B2|2000-09-28|2009-12-15|Nanocyte Inc.|Use of stinging cells/capsules for the delivery of active agents to keratinous substances|
    US20100030340A1|1998-06-30|2010-02-04|Wolfinbarger Jr Lloyd|Plasticized Grafts and Methods of Making and Using Same|
    US7736388B2|1999-04-09|2010-06-15|Evalve, Inc.|Fixation devices, systems and methods for engaging tissue|
    US7753923B2|1999-04-09|2010-07-13|Evalve, Inc.|Leaflet suturing|
    US7811296B2|1999-04-09|2010-10-12|Evalve, Inc.|Fixation devices for variation in engagement of tissue|
    US7981139B2|2002-03-01|2011-07-19|Evalve, Inc|Suture anchors and methods of use|
    US7981123B2|1997-09-12|2011-07-19|Evalve, Inc.|Surgical device for connecting soft tissue|
    US8029518B2|1999-04-09|2011-10-04|Evalve, Inc.|Methods and devices for capturing and fixing leaflets in valve repair|
    US8052592B2|2005-09-27|2011-11-08|Evalve, Inc.|Methods and devices for tissue grasping and assessment|
    US8123703B2|1999-04-09|2012-02-28|Evalve, Inc.|Steerable access sheath and methods of use|
    US8216256B2|1999-04-09|2012-07-10|Evalve, Inc.|Detachment mechanism for implantable fixation devices|
    US8343174B2|1999-04-09|2013-01-01|Evalve, Inc.|Locking mechanisms for fixation devices and methods of engaging tissue|
    US20130042957A1|2010-04-22|2013-02-21|Carmat|Method for obtaining a composite hemocompatible material and resulting material|
    US8563232B2|2000-09-12|2013-10-22|Lifenet Health|Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced|
    US20140142371A1|2006-12-07|2014-05-22|Stanley Batiste|Bypass Configuration and Method of Construction|
    US9150318B1|2009-01-02|2015-10-06|Lifecell Corporation|Method for sterilizing an acellular tissue matrix|
    US9320830B2|2007-12-21|2016-04-26|Edwards Lifesciences Corporation|Bioprosthetic tissue with reduced calcification|
    US9351829B2|2010-11-17|2016-05-31|Edwards Lifesciences Corporation|Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability|
    DE102015118789A1|2015-11-03|2017-05-04|Biotronik Ag|Method for reducing paravalvular leakage with decellularized tissue|
    US9744043B2|2007-07-16|2017-08-29|Lifenet Health|Crafting of cartilage|
    US20170265997A1|2002-01-04|2017-09-21|Colibri Heart Valve Llc|Percutaneously implantable replacement heart valve device and method of making same|
    US20180055635A1|2013-02-11|2018-03-01|Cook Medical Technologies Llc|Expandable Support Frame and Medical Device|
    US20180099078A1|2016-10-07|2018-04-12|Nuheart As|Transcatheter device and system for the delivery of intracorporeal devices|
    US10188392B2|2014-12-19|2019-01-29|Abbott Cardiovascular Systems, Inc.|Grasping for tissue repair|
    US10238495B2|2015-10-09|2019-03-26|Evalve, Inc.|Delivery catheter handle and methods of use|
    US10238494B2|2015-06-29|2019-03-26|Evalve, Inc.|Self-aligning radiopaque ring|
    US10314586B2|2016-12-13|2019-06-11|Evalve, Inc.|Rotatable device and method for fixing tricuspid valve tissue|
    US10363138B2|2016-11-09|2019-07-30|Evalve, Inc.|Devices for adjusting the curvature of cardiac valve structures|
    US10376673B2|2015-06-19|2019-08-13|Evalve, Inc.|Catheter guiding system and methods|
    US10390943B2|2014-03-17|2019-08-27|Evalve, Inc.|Double orifice device for transcatheter mitral valve replacement|
    US10398553B2|2016-11-11|2019-09-03|Evalve, Inc.|Opposing disk device for grasping cardiac valve tissue|
    US10413408B2|2015-08-06|2019-09-17|Evalve, Inc.|Delivery catheter systems, methods, and devices|
    US10426616B2|2016-11-17|2019-10-01|Evalve, Inc.|Cardiac implant delivery system|
    US10509392B2|2014-04-01|2019-12-17|X Development Llc|Runtime controller for robotic manufacturing system|
    US10524912B2|2015-04-02|2020-01-07|Abbott Cardiovascular Systems, Inc.|Tissue fixation devices and methods|
    US10631871B2|2003-05-19|2020-04-28|Evalve, Inc.|Fixation devices, systems and methods for engaging tissue|
    US10667815B2|2015-07-21|2020-06-02|Evalve, Inc.|Tissue grasping devices and related methods|
    US10722316B2|2013-11-06|2020-07-28|Edwards Lifesciences Corporation|Bioprosthetic heart valves having adaptive seals to minimize paravalvular leakage|
    US10736632B2|2016-07-06|2020-08-11|Evalve, Inc.|Methods and devices for valve clip excision|
    US10743876B2|2011-09-13|2020-08-18|Abbott Cardiovascular Systems Inc.|System for fixation of leaflets of a heart valve|
    US10779837B2|2016-12-08|2020-09-22|Evalve, Inc.|Adjustable arm device for grasping tissues|
    US11065119B2|2017-05-12|2021-07-20|Evalve, Inc.|Long arm valve repair clip|
    US11229435B2|2019-01-07|2022-01-25|Abbott Cardiovascular Systems Inc.|Grasping for tissue repair|US2106261A|1936-11-30|1938-01-25|John A Weidemann|Method of fixing and preserving gross anatomical specimens and the like|
    US2610625A|1947-10-14|1952-09-16|Armour & Co|Surgical sponge and the preparation thereof|
    US2645618A|1950-08-29|1953-07-14|Technicon Chemical Company Inc|Clearing agents for histological tissue|
    GB716161A|1951-11-22|1954-09-29|Paul Niehans|Method of preserving preparations of cells of animal organs|
    US2659986A|1951-12-12|1953-11-24|Cutter Lab|Method of drying human serum albumin and other heat sensitive biologically active proteins|
    US3257279A|1962-07-31|1966-06-21|Schain Philip|Water-soluble medium for tissue infiltrating and embedding|
    CH528266A|1969-11-26|1972-09-30|Orsymonde|Process for the preparation of a lyophilized composition for cosmetic or hygienic use|
    US4280954A|1975-07-15|1981-07-28|Massachusetts Institute Of Technology|Crosslinked collagen-mucopolysaccharide composite materials|
    JPS6045602B2|1978-09-28|1985-10-11|Masataka Katagiri||
    DE2906650C2|1979-02-21|1989-05-24|Pfrimmer-Viggo Gmbh & Co Kg, 8520 Erlangen, De||
    EP0037381B1|1980-03-31|1984-10-17|Solco Basel AG|Method of making organic grafts|
    US4357274A|1981-08-06|1982-11-02|Intermedicat Gmbh|Process for the manufacture of sclero protein transplants with increased biological stability|
    US4578067A|1982-04-12|1986-03-25|Alcon Inc.|Hemostatic-adhesive, collagen dressing for severed biological surfaces|
    JPS6320143B2|1982-04-19|1988-04-26|Koken Kk||
    US4801299A|1983-06-10|1989-01-31|University Patents, Inc.|Body implants of extracellular matrix and means and methods of making and using such implants|
    CA1295796C|1984-03-27|1992-02-18|Conrad Whyne|Biodegradable matrix and methods for producing same|
    EP0241838B1|1986-04-07|1992-04-15|Agency Of Industrial Science And Technology|Antithrombogenic material|
    US4760131A|1986-04-23|1988-07-26|Collagen Corporation|Wound-healing composition|
    US4911915A|1987-10-13|1990-03-27|Richard-Allan Medical Industries|Method of processing tissue specimens and dehydrant solvent for use therein|
    US5746775A|1988-04-01|1998-05-05|The Board Of Regent6S Of The University Of Michigan|Method of making calcification-resistant bioprosthetic tissue|
    US5131850A|1989-11-03|1992-07-21|Cryolife, Inc.|Method for cryopreserving musculoskeletal tissues|
    JPH07100B2|1990-01-31|1995-01-11|グンゼ株式会社|Method of drying collagen sponge|
    US5336616A|1990-09-12|1994-08-09|Lifecell Corporation|Method for processing and preserving collagen-based tissues for transplantation|
    US5476516A|1992-03-13|1995-12-19|Albert Einstein College Of Medicine Of Yeshiva University|Anticalcification treatment for aldehyde-tanned biological tissue|
    DE4223706A1|1992-07-18|1994-01-20|Henkel Kgaa|Use of Guerbet alcohols to prevent fat rash on leather|
    US5518878A|1993-09-15|1996-05-21|Organogenesis Inc.|Cryopreservation of cultured skin or cornea equivalents with agitation|
    US5447536A|1994-02-17|1995-09-05|Biomedical Design, Inc.|Method for fixation of biological tissue|
    US5558875A|1994-06-06|1996-09-24|Wang; Su|Method of preparing collagenous tissue|
    US5931969A|1994-07-29|1999-08-03|Baxter International Inc.|Methods and apparatuses for treating biological tissue to mitigate calcification|
    US5635344A|1994-12-07|1997-06-03|Cedra Corp.|Shipping medium for organ-derived cells|
    US5674290A|1995-04-05|1997-10-07|Li; Shu-Tung|Water-stabilized biopolymeric implants|
    AU3950297A|1996-08-21|1998-03-06|Sulzer Vascutek Limited|Method of sterilising material for implantation|
    AU746318B2|1997-04-11|2002-04-18|Cryolife, Inc.|Tissue decellularization|US6006134A|1998-04-30|1999-12-21|Medtronic, Inc.|Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers|
    US7749245B2|2000-01-27|2010-07-06|Medtronic, Inc.|Cardiac valve procedure methods and devices|
    US6352708B1|1999-10-14|2002-03-05|The International Heart Institute Of Montana Foundation|Solution and method for treating autologous tissue for implant operation|
    US8016877B2|1999-11-17|2011-09-13|Medtronic Corevalve Llc|Prosthetic valve for transluminal delivery|
    US8579966B2|1999-11-17|2013-11-12|Medtronic Corevalve Llc|Prosthetic valve for transluminal delivery|
    US7018406B2|1999-11-17|2006-03-28|Corevalve Sa|Prosthetic valve for transluminal delivery|
    US8241274B2|2000-01-19|2012-08-14|Medtronic, Inc.|Method for guiding a medical device|
    US6358277B1|2000-06-21|2002-03-19|The International Heart Institute Of Montana Foundation|Atrio-ventricular valvular device|
    AU7308801A|2000-06-30|2002-01-30|Viacor Inc|Intravascular filter with debris entrapment mechanism|
    US8623077B2|2001-06-29|2014-01-07|Medtronic, Inc.|Apparatus for replacing a cardiac valve|
    US7544206B2|2001-06-29|2009-06-09|Medtronic, Inc.|Method and apparatus for resecting and replacing an aortic valve|
    US8771302B2|2001-06-29|2014-07-08|Medtronic, Inc.|Method and apparatus for resecting and replacing an aortic valve|
    US20020022860A1|2000-08-18|2002-02-21|Borillo Thomas E.|Expandable implant devices for filtering blood flow from atrial appendages|
    CA2420113A1|2000-08-24|2002-02-28|Osteotech, Inc.|Method of treating and dehydrating bone for implantation|
    US7726319B1|2000-08-24|2010-06-01|Osteotech, Inc.|Method for removal of water associated with bone while diminishing the dimensional changes associated with lyophilization|
    US7097659B2|2001-09-07|2006-08-29|Medtronic, Inc.|Fixation band for affixing a prosthetic heart valve to tissue|
    FR2826863B1|2001-07-04|2003-09-26|Jacques Seguin|ASSEMBLY FOR THE PLACEMENT OF A PROSTHETIC VALVE IN A BODY CONDUIT|
    FR2828091B1|2001-07-31|2003-11-21|Seguin Jacques|ASSEMBLY ALLOWING THE PLACEMENT OF A PROTHETIC VALVE IN A BODY DUCT|
    US6878168B2|2002-01-03|2005-04-12|Edwards Lifesciences Corporation|Treatment of bioprosthetic tissues to mitigate post implantation calcification|
    US7160320B2|2002-04-16|2007-01-09|The International Heart Institute Of Montana Foundation|Reed valve for implantation into mammalian blood vessels and heart with optional temporary or permanent support|
    US7125418B2|2002-04-16|2006-10-24|The International Heart Institute Of Montana Foundation|Sigmoid valve and method for its percutaneous implantation|
    US8721713B2|2002-04-23|2014-05-13|Medtronic, Inc.|System for implanting a replacement valve|
    US7008763B2|2002-09-23|2006-03-07|Cheung David T|Method to treat collagenous connective tissue for implant remodeled by host cells into living tissue|
    US9579194B2|2003-10-06|2017-02-28|Medtronic ATS Medical, Inc.|Anchoring structure with concave landing zone|
    US7186265B2|2003-12-10|2007-03-06|Medtronic, Inc.|Prosthetic cardiac valves and systems and methods for implanting thereof|
    US8052749B2|2003-12-23|2011-11-08|Sadra Medical, Inc.|Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements|
    US8603160B2|2003-12-23|2013-12-10|Sadra Medical, Inc.|Method of using a retrievable heart valve anchor with a sheath|
    US7329279B2|2003-12-23|2008-02-12|Sadra Medical, Inc.|Methods and apparatus for endovascularly replacing a patient's heart valve|
    US9005273B2|2003-12-23|2015-04-14|Sadra Medical, Inc.|Assessing the location and performance of replacement heart valves|
    US8343213B2|2003-12-23|2013-01-01|Sadra Medical, Inc.|Leaflet engagement elements and methods for use thereof|
    US8182528B2|2003-12-23|2012-05-22|Sadra Medical, Inc.|Locking heart valve anchor|
    EP2529699B1|2003-12-23|2014-01-29|Sadra Medical, Inc.|Repositionable heart valve|
    US20050137694A1|2003-12-23|2005-06-23|Haug Ulrich R.|Methods and apparatus for endovascularly replacing a patient's heart valve|
    US7988724B2|2003-12-23|2011-08-02|Sadra Medical, Inc.|Systems and methods for delivering a medical implant|
    US7824443B2|2003-12-23|2010-11-02|Sadra Medical, Inc.|Medical implant delivery and deployment tool|
    US7381219B2|2003-12-23|2008-06-03|Sadra Medical, Inc.|Low profile heart valve and delivery system|
    US7824442B2|2003-12-23|2010-11-02|Sadra Medical, Inc.|Methods and apparatus for endovascularly replacing a heart valve|
    US7748389B2|2003-12-23|2010-07-06|Sadra Medical, Inc.|Leaflet engagement elements and methods for use thereof|
    US8840663B2|2003-12-23|2014-09-23|Sadra Medical, Inc.|Repositionable heart valve method|
    US7959666B2|2003-12-23|2011-06-14|Sadra Medical, Inc.|Methods and apparatus for endovascularly replacing a heart valve|
    US9526609B2|2003-12-23|2016-12-27|Boston Scientific Scimed, Inc.|Methods and apparatus for endovascularly replacing a patient's heart valve|
    US7445631B2|2003-12-23|2008-11-04|Sadra Medical, Inc.|Methods and apparatus for endovascularly replacing a patient's heart valve|
    US20120041550A1|2003-12-23|2012-02-16|Sadra Medical, Inc.|Methods and Apparatus for Endovascular Heart Valve Replacement Comprising Tissue Grasping Elements|
    US8579962B2|2003-12-23|2013-11-12|Sadra Medical, Inc.|Methods and apparatus for performing valvuloplasty|
    ITTO20040135A1|2004-03-03|2004-06-03|Sorin Biomedica Cardio Spa|CARDIAC VALVE PROSTHESIS|
    US7648676B2|2004-04-20|2010-01-19|Rti Biologics, Inc.|Process and apparatus for treating implants comprising soft tissue|
    BRPI0510107A|2004-04-23|2007-09-25|3F Therapeutics Inc|implantable protein valve|
    US7780725B2|2004-06-16|2010-08-24|Sadra Medical, Inc.|Everting heart valve|
    US20060052867A1|2004-09-07|2006-03-09|Medtronic, Inc|Replacement prosthetic heart valve, system and method of implant|
    US8562672B2|2004-11-19|2013-10-22|Medtronic, Inc.|Apparatus for treatment of cardiac valves and method of its manufacture|
    ITTO20050074A1|2005-02-10|2006-08-11|Sorin Biomedica Cardio Srl|CARDIAC VALVE PROSTHESIS|
    US7962208B2|2005-04-25|2011-06-14|Cardiac Pacemakers, Inc.|Method and apparatus for pacing during revascularization|
    US7914569B2|2005-05-13|2011-03-29|Medtronics Corevalve Llc|Heart valve prosthesis and methods of manufacture and use|
    US7712606B2|2005-09-13|2010-05-11|Sadra Medical, Inc.|Two-part package for medical implant|
    WO2007038540A1|2005-09-26|2007-04-05|Medtronic, Inc.|Prosthetic cardiac and venous valves|
    US8287584B2|2005-11-14|2012-10-16|Sadra Medical, Inc.|Medical implant deployment tool|
    US20070213813A1|2005-12-22|2007-09-13|Symetis Sa|Stent-valves for valve replacement and associated methods and systems for surgery|
    US9078781B2|2006-01-11|2015-07-14|Medtronic, Inc.|Sterile cover for compressible stents used in percutaneous device delivery systems|
    WO2007123658A1|2006-03-28|2007-11-01|Medtronic, Inc.|Prosthetic cardiac valve formed from pericardium material and methods of making same|
    US7625403B2|2006-04-04|2009-12-01|Medtronic Vascular, Inc.|Valved conduit designed for subsequent catheter delivered valve therapy|
    US7740655B2|2006-04-06|2010-06-22|Medtronic Vascular, Inc.|Reinforced surgical conduit for implantation of a stented valve therein|
    US7591848B2|2006-04-06|2009-09-22|Medtronic Vascular, Inc.|Riveted stent valve for percutaneous use|
    US7524331B2|2006-04-06|2009-04-28|Medtronic Vascular, Inc.|Catheter delivered valve having a barrier to provide an enhanced seal|
    US8834564B2|2006-09-19|2014-09-16|Medtronic, Inc.|Sinus-engaging valve fixation member|
    US8052750B2|2006-09-19|2011-11-08|Medtronic Ventor Technologies Ltd|Valve prosthesis fixation techniques using sandwiching|
    US8784478B2|2006-10-16|2014-07-22|Medtronic Corevalve, Inc.|Transapical delivery system with ventruculo-arterial overlfow bypass|
    US8007992B2|2006-10-27|2011-08-30|Edwards Lifesciences Corporation|Method of treating glutaraldehyde-fixed pericardial tissue with a non-aqueous mixture of glycerol and a C1-C3 alcohol|
    EP2104470A2|2006-12-06|2009-09-30|Medtronic Corevalve, LLC.|System and method for transapical delivery of an annulus anchored self-expanding valve|
    KR100803384B1|2007-01-15|2008-02-13|한스바이오메드 주식회사|Long-term preservation method for skin tissue|
    WO2008089365A2|2007-01-19|2008-07-24|The Cleveland Clinic Foundation|Method for implanting a cardiovascular valve|
    US7871436B2|2007-02-16|2011-01-18|Medtronic, Inc.|Replacement prosthetic heart valves and methods of implantation|
    FR2915087B1|2007-04-20|2021-11-26|Corevalve Inc|IMPLANT FOR TREATMENT OF A HEART VALVE, IN PARTICULAR OF A MITRAL VALVE, EQUIPMENT INCLUDING THIS IMPLANT AND MATERIAL FOR PLACING THIS IMPLANT.|
    US9101691B2|2007-06-11|2015-08-11|Edwards Lifesciences Corporation|Methods for pre-stressing and capping bioprosthetic tissue|
    US8747458B2|2007-08-20|2014-06-10|Medtronic Ventor Technologies Ltd.|Stent loading tool and method for use thereof|
    US10856970B2|2007-10-10|2020-12-08|Medtronic Ventor Technologies Ltd.|Prosthetic heart valve for transfemoral delivery|
    US9848981B2|2007-10-12|2017-12-26|Mayo Foundation For Medical Education And Research|Expandable valve prosthesis with sealing mechanism|
    US8735054B1|2008-01-04|2014-05-27|Lifecell Corporation|Acellular tissue matrix preservation solution|
    US9149358B2|2008-01-24|2015-10-06|Medtronic, Inc.|Delivery systems for prosthetic heart valves|
    CA2714062A1|2008-01-24|2009-07-30|Medtronic, Inc.|Stents for prosthetic heart valves|
    EP2254513B1|2008-01-24|2015-10-28|Medtronic, Inc.|Stents for prosthetic heart valves|
    US8157852B2|2008-01-24|2012-04-17|Medtronic, Inc.|Delivery systems and methods of implantation for prosthetic heart valves|
    US9393115B2|2008-01-24|2016-07-19|Medtronic, Inc.|Delivery systems and methods of implantation for prosthetic heart valves|
    US9089422B2|2008-01-24|2015-07-28|Medtronic, Inc.|Markers for prosthetic heart valves|
    BR112012021347A2|2008-02-26|2019-09-24|Jenavalve Tecnology Inc|stent for positioning and anchoring a valve prosthesis at an implantation site in a patient's heart|
    US20090264989A1|2008-02-28|2009-10-22|Philipp Bonhoeffer|Prosthetic heart valve systems|
    US8313525B2|2008-03-18|2012-11-20|Medtronic Ventor Technologies, Ltd.|Valve suturing and implantation procedures|
    US8430927B2|2008-04-08|2013-04-30|Medtronic, Inc.|Multiple orifice implantable heart valve and methods of implantation|
    US8696743B2|2008-04-23|2014-04-15|Medtronic, Inc.|Tissue attachment devices and methods for prosthetic heart valves|
    US8312825B2|2008-04-23|2012-11-20|Medtronic, Inc.|Methods and apparatuses for assembly of a pericardial prosthetic heart valve|
    US8840661B2|2008-05-16|2014-09-23|Sorin Group Italia S.R.L.|Atraumatic prosthetic heart valve prosthesis|
    WO2010031060A1|2008-09-15|2010-03-18|Medtronic Ventor Technologies Ltd.|Prosthetic heart valve having identifiers for aiding in radiographic positioning|
    US8721714B2|2008-09-17|2014-05-13|Medtronic Corevalve Llc|Delivery system for deployment of medical devices|
    EP3238661B1|2008-10-10|2019-05-22|Boston Scientific Scimed, Inc.|Medical devices and delivery systems for delivering medical devices|
    US8137398B2|2008-10-13|2012-03-20|Medtronic Ventor Technologies Ltd|Prosthetic valve having tapered tip when compressed for delivery|
    US8986361B2|2008-10-17|2015-03-24|Medtronic Corevalve, Inc.|Delivery system for deployment of medical devices|
    US8834563B2|2008-12-23|2014-09-16|Sorin Group Italia S.R.L.|Expandable prosthetic valve having anchoring appendages|
    US8512397B2|2009-04-27|2013-08-20|Sorin Group Italia S.R.L.|Prosthetic vascular conduit|
    US8808369B2|2009-10-05|2014-08-19|Mayo Foundation For Medical Education And Research|Minimally invasive aortic valve replacement|
    US9226826B2|2010-02-24|2016-01-05|Medtronic, Inc.|Transcatheter valve structure and methods for valve delivery|
    CA2800232C|2010-03-01|2015-08-11|Colibri Heart Valve Llc|Percutaneously deliverable heart valve and methods associated therewith|
    BR112012023769B1|2010-03-23|2020-11-10|Edwards Lifesciences Corporation|method for preparing bioprosthetic tissue membrane material|
    US8652204B2|2010-04-01|2014-02-18|Medtronic, Inc.|Transcatheter valve with torsion spring fixation and related systems and methods|
    IT1400327B1|2010-05-21|2013-05-24|Sorin Biomedica Cardio Srl|SUPPORT DEVICE FOR VALVULAR PROSTHESIS AND CORRESPONDING CORRESPONDENT.|
    US8906601B2|2010-06-17|2014-12-09|Edwardss Lifesciences Corporation|Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates|
    JP5936610B2|2010-06-28|2016-06-22|コリブリ ハート バルブ エルエルシーＣｏｌｉｂｒｉ Ｈｅａｒｔ Ｖａｌｖｅ Ｌｌｃ|Device for intracavity delivery of an intravascular injection device|
    JP5874727B2|2010-09-01|2016-03-02|メドトロニック ヴァスキュラー ゴールウェイ|Prosthetic valve support structure|
    US9333075B2|2010-09-10|2016-05-10|Symetis Sa|Valve replacement devices, delivery device for a valve replacement device and method of production of a valve replacement device|
    AU2011303580B2|2010-09-13|2016-03-10|Singapore Health Services Pte Ltd|Method for performing a reversible refractive procedure|
    US9737400B2|2010-12-14|2017-08-22|Colibri Heart Valve Llc|Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets|
    DE102011008604A1|2011-01-14|2012-07-19|Tutogen Medical Gmbh|Preparation of a graft of animal dermis with sodium sulfide solution|
    EP2486894B1|2011-02-14|2021-06-09|Sorin Group Italia S.r.l.|Sutureless anchoring device for cardiac valve prostheses|
    ES2641902T3|2011-02-14|2017-11-14|Sorin Group Italia S.R.L.|Sutureless anchoring device for cardiac valve prostheses|
    WO2012127309A1|2011-03-21|2012-09-27|Ontorfano Matteo|Disk-based valve apparatus and method for the treatment of valve dysfunction|
    JP2014527425A|2011-07-12|2014-10-16|ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ．|Linkage system for medical devices|
    US9131926B2|2011-11-10|2015-09-15|Boston Scientific Scimed, Inc.|Direct connect flush system|
    US8940014B2|2011-11-15|2015-01-27|Boston Scientific Scimed, Inc.|Bond between components of a medical device|
    US8951243B2|2011-12-03|2015-02-10|Boston Scientific Scimed, Inc.|Medical device handle|
    US9277993B2|2011-12-20|2016-03-08|Boston Scientific Scimed, Inc.|Medical device delivery systems|
    US9510945B2|2011-12-20|2016-12-06|Boston Scientific Scimed Inc.|Medical device handle|
    EP2609893B1|2011-12-29|2014-09-03|Sorin Group Italia S.r.l.|A kit for implanting prosthetic vascular conduits|
    WO2013112547A1|2012-01-25|2013-08-01|Boston Scientific Scimed, Inc.|Valve assembly with a bioabsorbable gasket and a replaceable valve implant|
    US9883941B2|2012-06-19|2018-02-06|Boston Scientific Scimed, Inc.|Replacement heart valve|
    US20140005793A1|2012-06-21|2014-01-02|Keith Cameron Koford|Novel biological implant compositions, implants and methods|
    US10238771B2|2012-11-08|2019-03-26|Edwards Lifesciences Corporation|Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system|
    WO2014179763A1|2013-05-03|2014-11-06|Medtronic Inc.|Valve delivery tool|
    RU2525197C1|2013-05-28|2014-08-10|Владимир Андреевич Болсуновский|Cardiovascular homograft , method for preparing homograft, homograft tissue exposure medium |
    US9561103B2|2013-07-17|2017-02-07|Cephea Valve Technologies, Inc.|System and method for cardiac valve repair and replacement|
    AU2014296259B2|2013-07-30|2017-04-27|Musculoskeletal Transplant Foundation|Acellular soft tissue-derived matrices and methods for preparing same|
    CN105491978A|2013-08-30|2016-04-13|耶拿阀门科技股份有限公司|Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame|
    US9615922B2|2013-09-30|2017-04-11|Edwards Lifesciences Corporation|Method and apparatus for preparing a contoured biological tissue|
    US10959839B2|2013-10-08|2021-03-30|Edwards Lifesciences Corporation|Method for directing cellular migration patterns on a biological tissue|
    US9801910B2|2014-03-17|2017-10-31|Ethicon, Inc.|Decellularized pleural matrix|
    EP2926840B1|2014-04-02|2018-05-09|Biotronik AG|Method for the treatment of biological tissue for dry use in an implant|
    US9901445B2|2014-11-21|2018-02-27|Boston Scientific Scimed, Inc.|Valve locking mechanism|
    WO2016093877A1|2014-12-09|2016-06-16|Cephea Valve Technologies, Inc.|Replacement cardiac valves and methods of use and manufacture|
    US10449043B2|2015-01-16|2019-10-22|Boston Scientific Scimed, Inc.|Displacement based lock and release mechanism|
    US9861477B2|2015-01-26|2018-01-09|Boston Scientific Scimed Inc.|Prosthetic heart valve square leaflet-leaflet stitch|
    WO2016126524A1|2015-02-03|2016-08-11|Boston Scientific Scimed, Inc.|Prosthetic heart valve having tubular seal|
    US9788942B2|2015-02-03|2017-10-17|Boston Scientific Scimed Inc.|Prosthetic heart valve having tubular seal|
    US10285809B2|2015-03-06|2019-05-14|Boston Scientific Scimed Inc.|TAVI anchoring assist device|
    US10426617B2|2015-03-06|2019-10-01|Boston Scientific Scimed, Inc.|Low profile valve locking mechanism and commissure assembly|
    US10080652B2|2015-03-13|2018-09-25|Boston Scientific Scimed, Inc.|Prosthetic heart valve having an improved tubular seal|
    CN106190949B|2015-05-08|2020-04-10|上海微创心通医疗科技有限公司|Dry animal-derived collagen fiber tissue material, preparation method thereof and bioprosthesis|
    WO2016183526A1|2015-05-14|2016-11-17|Cephea Valve Technologies, Inc.|Replacement mitral valves|
    EP3294220A4|2015-05-14|2019-02-13|Cephea Valve Technologies, Inc.|Cardiac valve delivery devices and systems|
    US10335277B2|2015-07-02|2019-07-02|Boston Scientific Scimed Inc.|Adjustable nosecone|
    US10195392B2|2015-07-02|2019-02-05|Boston Scientific Scimed, Inc.|Clip-on catheter|
    US10179041B2|2015-08-12|2019-01-15|Boston Scientific Scimed Icn.|Pinless release mechanism|
    US10136991B2|2015-08-12|2018-11-27|Boston Scientific Scimed Inc.|Replacement heart valve implant|
    US11052175B2|2015-08-19|2021-07-06|Musculoskeletal Transplant Foundation|Cartilage-derived implants and methods of making and using same|
    US10779940B2|2015-09-03|2020-09-22|Boston Scientific Scimed, Inc.|Medical device handle|
    US10342660B2|2016-02-02|2019-07-09|Boston Scientific Inc.|Tensioned sheathing aids|
    US10245136B2|2016-05-13|2019-04-02|Boston Scientific Scimed Inc.|Containment vessel with implant sheathing guide|
    US10583005B2|2016-05-13|2020-03-10|Boston Scientific Scimed, Inc.|Medical device handle|
    EP3454795A1|2016-05-13|2019-03-20|JenaValve Technology, Inc.|Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system|
    US10201416B2|2016-05-16|2019-02-12|Boston Scientific Scimed, Inc.|Replacement heart valve implant with invertible leaflets|
    CN106561635A|2016-11-07|2017-04-19|上海纽脉太惟医疗科技有限公司|Method for dry preservation of biological tissue|
    CN110621260A|2017-01-23|2019-12-27|科菲瓣膜技术有限公司|Replacement mitral valve|
    AU2018203053B2|2017-01-23|2020-03-05|Cephea Valve Technologies, Inc.|Replacement mitral valves|
    EP3573579A1|2017-01-27|2019-12-04|JenaValve Technology, Inc.|Heart valve mimicry|
    CN106913909B|2017-02-27|2020-09-01|杭州启明医疗器械股份有限公司|Dry artificial biological valve and preparation method thereof|
    EP3634311A1|2017-06-08|2020-04-15|Boston Scientific Scimed, Inc.|Heart valve implant commissure support structure|
    WO2019006256A1|2017-06-29|2019-01-03|St. Jude Medical, Cardiology Division, Inc.|Method of preparing calcification-resistant bioprosthetic tissue|
    EP3661458A1|2017-08-01|2020-06-10|Boston Scientific Scimed, Inc.|Medical implant locking mechanism|
    CN111225633A|2017-08-16|2020-06-02|波士顿科学国际有限公司|Replacement heart valve coaptation assembly|
    CN107802889B|2017-12-08|2019-11-01|上海微创心通医疗科技有限公司|A kind of animal derived collagenous tissue material of dry state and preparation method thereof|
    JP2021511144A|2018-01-19|2021-05-06|ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ．|Induction mode indwelling sensor for transcatheter valve system|
    EP3749252A1|2018-02-07|2020-12-16|Boston Scientific Scimed, Inc.|Medical device delivery system with alignment feature|
    法律状态:
    1998-06-24| AS| Assignment|Owner name: INTERNATIONAL HEART INSTITUTE OF MONTANA, MONTANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DURAN, CARLOS M.C.;CHEUNG, DAVID T.;PANG, DAVID C.;REEL/FRAME:009295/0134;SIGNING DATES FROM 19980604 TO 19980615 |
    2003-09-18| STCF| Information on status: patent grant|Free format text: PATENTED CASE |
    2007-04-25| REMI| Maintenance fee reminder mailed|
    2007-05-07| SULP| Surcharge for late payment|
    2007-05-07| FPAY| Fee payment|Year of fee payment: 4 |
    2011-02-11| FPAY| Fee payment|Year of fee payment: 8 |
    2015-03-18| FPAY| Fee payment|Year of fee payment: 12 |
    优先权:
    申请号 | 申请日 | 专利标题
    US09/103,874|US6630001B2|1998-06-24|1998-06-24|Compliant dehyrated tissue for implantation and process of making the same|US09/103,874| US6630001B2|1998-06-24|1998-06-24|Compliant dehyrated tissue for implantation and process of making the same|
    DK99931880T| DK1089776T3|1998-06-24|1999-06-23|Method of preparing deformable dehydrated tissue for implantation|
    PCT/US1999/014247| WO1999066967A1|1998-06-24|1999-06-23|Process for making compliant dehydrated tissue for implantation|
    ES99931880T| ES2178449T3|1998-06-24|1999-06-23|PROCEDURE OF PRODUCTION OF A DEHYDRATED FLEXIBLE FABRIC DESTINED TO BE IMPLANTED.|
    EP99931880A| EP1089776B1|1998-06-24|1999-06-23|Process for making compliant dehydrated tissue for implantation|
    AT99931880T| AT218067T|1998-06-24|1999-06-23|METHOD FOR PRODUCING ELASTIC DEHYDRATED IMPLANT TISSUE|
    DE69901612T| DE69901612T2|1998-06-24|1999-06-23|METHOD FOR PRODUCING ELASTIC DEHYDRATED IMPLANT TISSUE|
    CNB998077364A| CN1245222C|1998-06-24|1999-06-23|Process for making compliant dehydrated tissue for implantation|
    BRPI9912180-8A| BR9912180B1|1998-06-24|1999-06-23|Soft, foldable fabric sample and process for its preparation.|
    CA002335604A| CA2335604C|1998-06-24|1999-06-23|Process for making compliant dehydrated tissue for implantation|
    AU48298/99A| AU751506B2|1998-06-24|1999-06-23|Process for making compliant dehydrated tissue for implantation|
    US09/535,490| US6277555B1|1998-06-24|2000-03-24|Compliant dehydrated tissue for implantation and process of making the same|
    HK02100771.3A| HK1039284B|1998-06-24|2002-01-31|Process for making compliant dehydrated tissue for implantation|
    [返回顶部]